[Risk Factors associated with post-chemotherapy vomiting in patients with breast cancer (II): analysis of the duration of emesis]
OBJECTIVE: To identify the risk factors associated with the duration of emesis after high-dose chemotherapy in high risk breast cancer patients and to assess the predictive performance of a mathematical model. METHODS: Cox regression model was developed to predict the duration of emesis, and different prognostic factors were evaluated: anthropometric characteristics, cyclophosphamide and carboplatin clearance, administration of ondansetron or tropisetron, and emesis intensity classified as a function of emetic protection degree. RESULTS: The emetic episodes started and finished, 3 and 8 days, from the beginning of chemotherapy, respectively. The probability of finishing the emesis episodes is 2 times higher in patients receiving ondansetron treatment with than in those receiving tropisetron and, 8 times higher in patient with major or complete emetic protection than in those with minor emetic protection or treatment failure. CONCLUSION: The antiemetic protection with ondansetron after high dose of chemotherapy in high risk breast cancer patients is more effective option than tropisetron because the duration of emesis is lower.
Pérez Ruixo
JJ
J
Global Clinical Pharmacokinetics and Pharmacology Division. Johnson and Johnson Pharmaceutical Research and Development. Division of Janssen N.V. Belgium.
Llopis García
MC
M
Casabo Alos
VG
V
Jiménez Torres
NV
N